摘要
目的:探讨4-羟基苯并恶唑-2-酮(HBOA)对四氯化碳(CCl4)诱导的大鼠肝纤维化的保护作用。方法:采用CCl4橄榄油溶液灌胃建立大鼠肝纤维化模型。第8周确定建模成功后,将雄性SD大鼠随机分成正常对照组,模型对照组,秋水仙碱阳性药组,HBOA高、中、低药物组。从第9周起,相应药物干预4周后,测定血清中总蛋白(TP),白蛋白(Alb)的含量以及肝组织中羟脯氨酸(Hyp)的含量;免疫组织法检测肝组织中α-平滑肌肌动蛋白(α-SMA)蛋白含量的表达; Westerns blot法检测肝组织中MAPK,P-MAPK,P38的蛋白含量的表达。结果:与模型组相比,HBOA可降低肝纤维化大鼠血清TP、Alb水平(P <0. 01)以及肝组织中Hyp水平(P <0. 01),HBOA高中低剂量组显著降低大鼠肝组织中的α-SMA蛋白的表达(P <0. 01),并显著下调MAPK,P-MAPK,P38的蛋白表达水平(P <0. 01)。结论:HBOA对CCl4诱导的肝纤维化大鼠有一定的改善作用,通过抑制MAPK的信号通路,显著减轻了CCl4诱导的纤维化。
OBJECTIVE To explore the potential mechanism by which 4-hydroxy-2(3 H)-benzoxazolone(HBOA)protects a-gainst hepatic fibrosis in rats induced by CCl4.METHODS A hepatic fibrosis model of rats was established by orally administering50%CCl4/olive oil for 12 weeks.Then,at the 8 th week,the successful model rats were randomly divided into a normal control group,a hepatic fibrosis model group,a colchicine group and three dose HBOA treatment groups.From the 9 th week,animals were treatedwith the drugs daily for 4 weeks.The changes of the serum indicators including total protein(TP),albumin(Alb)and liver tissue in-dicators hydroxyproline(Hyp)were determined.Moreover,the protein ofα-SMA in liver was examined by immunohistochemistry.Theexpressions of MAPK,P-MAPK and P38 protein were detected with Western blot.RESULTS Compared with the model group,thelevels of TP and Alb in the rat serum and Hyp in liver tissues of HBOA groups were significantly decreased(P<0.01).The proteinexpressions ofα-SMA in liver tissues of HBOA groups(100,75,50 mg·kg-1)were decreased(P<0.01),and the expressions ofMAPK,P-MAPK and P38 protein were also down regulated by HBOA(P<0.01).CONCLUSION HBOA have beneficial effects a-gainst liver fibrosis in rats induced by CCl4.The present study results indicate that HBOA significantly alleviates CCl4-induced liver fi-brosis through suppressing the MAPK signaling pathway.
作者
孙雪梅
黄秀昆
朱勋帅
刘林
林兴
林军
SUN Xue-mei;HUANG Xiu-kun;ZHU Xun-shuai;LIU Lin;LIN Xing;LIN Jun(Department of Pharmacology,Guangxi Medical University,Guangxi Nanning 530021,China)
出处
《中国医院药学杂志》
CAS
北大核心
2019年第1期25-28,共4页
Chinese Journal of Hospital Pharmacy
基金
国家自然科学基金(编号:81660106)